Lakeshore Veterinary Specialists, Glendale, WI, USA.
Biomedical Sciences, Iowa State University, Ames, IA, USA.
J Feline Med Surg. 2021 Dec;23(12):1176-1182. doi: 10.1177/1098612X211001283. Epub 2021 Mar 22.
The aim of this study was to determine if male cats treated with 7 days of prazosin following relief of urethral obstruction (UO) experienced decreased rates of recurrent urethral obstruction (rUO) within 30 days vs those treated with 7 days of placebo.
All castrated male cats presenting for the first time with UO from May 2014 to August 2017 were eligible for enrollment. Exclusion criteria included the administration of medications or passage of a urinary catheter prior to referral, the presence of heart disease or hypertension requiring medication, prior treatment with glucocorticoids, non-steroidal anti-inflammatory medications, prazosin or phenoxybenzamine, or radiographic identification of cystoliths. Cats were treated with standardized anesthetic and analgesic protocols, standardized indwelling urinary catheter management, and were hospitalized for care. A random numbers table was generated prior to study initiation and cats were randomized to receive either prazosin (0.5 mg PO q12h for 7 days) or placebo in a blinded fashion. A 30-day follow-up with owners via telephone was performed to identify the rate of rUO. Cats that did not receive the full course of study medication were removed from the analysis. The study was unblinded at the end of data collection.
Eighty cats were enrolled and 65 cats completed the study; 12 were excluded because they did not receive the study medication. Sixteen of 65 cats experienced rUO (25%). Of the 16 cats experiencing rUO, five received placebo (n = 5/28 [18%]) and 11 received prazosin (n = 11/37 [30%]). Ten of the cats that experienced rUO reblocked while still hospitalized. There was no significant difference in frequency of rUO in cats treated with prazosin vs placebo ( = 0.27).
Prazosin administered at 0.5 mg PO q12h did not decrease the rate of rUO in this population of obstructed male cats vs placebo. These results further support evidence suggesting that prazosin may not be beneficial in prevention of feline rUO.
本研究旨在确定在解除尿道梗阻(UO)后接受 7 天普萘洛尔治疗的雄性猫与接受 7 天安慰剂治疗的雄性猫相比,30 天内复发性尿道梗阻(rUO)的发生率是否降低。
所有 2014 年 5 月至 2017 年 8 月首次因 UO 就诊且已绝育的雄性猫均有资格入组。排除标准包括转诊前使用药物或导尿管、存在需要药物治疗的心脏病或高血压、先前使用糖皮质激素、非甾体抗炎药、普萘洛尔或酚芐明、或放射影像学识别出膀胱结石。所有猫均接受标准化麻醉和镇痛方案、标准化留置导尿管管理,并住院接受治疗。在研究开始前生成随机数字表,并以盲法方式将猫随机分为接受普萘洛尔(0.5mg PO q12h 治疗 7 天)或安慰剂治疗。通过电话对猫主人进行 30 天随访以确定 rUO 的发生率。未接受完整研究药物治疗的猫将被从分析中剔除。在数据收集结束时,研究将解除盲法。
共纳入 80 只猫,其中 65 只猫完成了研究;12 只猫因未接受研究药物而被排除。65 只猫中有 16 只出现 rUO(25%)。在出现 rUO 的 16 只猫中,5 只接受安慰剂(n=5/28[18%]),11 只接受普萘洛尔(n=11/37[30%])。10 只出现 rUO 的猫在仍住院期间再次梗阻。接受普萘洛尔治疗的猫与接受安慰剂治疗的猫 rUO 发生率无显著差异(P=0.27)。
在本梗阻雄性猫群中,以 0.5mg PO q12h 给予普萘洛尔并未降低 rUO 的发生率,与安慰剂相比无显著差异。这些结果进一步支持了普萘洛尔可能无益于预防猫 rUO 的证据。